Chemistry: analytical and immunological testing – Biospecific ligand binding assay
Reexamination Certificate
2006-08-15
2006-08-15
Yu, Misook (Department: 1642)
Chemistry: analytical and immunological testing
Biospecific ligand binding assay
C436S518000, C435S007230
Reexamination Certificate
active
07091047
ABSTRACT:
Methods and kits for diagnosing tumorigenicity by measuring the concentration of GP88 in blood, plasma, serum, saliva, urine and other biological fluids. The methods and kits detect GP88 in biological fluids at a concentration as low as about 0.1 to 10 nanograms per milliliter and are useful for determining whether a patient has a tumorigenic condition, whether the patient is likely to be responsive to anti-tumorigenic therapies, and whether the treated patient is responding to anti-tumorigenic therapy by measuring the concentration of GP88 in the patient's serum or other biological fluid.
REFERENCES:
patent: 5416192 (1995-05-01), Shoyab et al.
patent: 6309826 (2001-10-01), Serrero
patent: 6511986 (2003-01-01), Zhang et al.
patent: WO 91/15510 (1991-10-01), None
patent: WO 93/15195 (1993-08-01), None
Runqing Lu, et al.—“Inhibition of PC cell-derived growth factor (PCDGF, epithelin/granulin precursor) expression by antisense PCDGF cDNA transfection inhibits tumorigenicity of the human breast carcinoma cell line MDA-MB-468,” PNAS, vol. 97, No. 8, Apr. 11, 2000, pp. 3993-3998.
Vijay Bhandari, et al.—“Isolation and sequence of the granulin precursor cDNA from human bone marrow reveals tandem cysteine-rich granulin domains,” Proc. Natl. Acad. Sci. USA, vol. 89, Mar. 1992, pp. 1715-1719.
Zhiheng He, et al.—“ProgranulinGene Expression Regulates Epithelial Cell Growth and Promotes Tumor Growthin Vivo1.” Can Cer Research 59, Jul. 1, 1999, pp. 3222-3229.
International Search Report dated May 13, 2003.
Effect of Testosterone on the Growth Properties and on Epidermal Growth Factor Receptor Expression in the Teratoma-derived Tumorigenic Cell Line 1246-3A, Serrero, G. et al., Cancer Research 52, 1992, pp. 4242-4247.
Molecular Biology of the Cell, Alberts, B., et al., Garland Publishing, Inc., 1983.
Growth Factors in Development, Transformation, and Tumorigenesis, Cross, M. et al., Cell, vol. 64, 1991, pp. 271-280.
Autocrine Secretion and Malignant Transformation of Cells, Sporn, M.B. et al., The New England Journal of Medicine, vol. 303, 1980, pp. 878-880.
Purification of an Autocrine Growth Factor Homologous with Mouse Epithelin Precursor from a Highly Tumorigenic Cell Line, Zhou, J. et al., The Journal of Biological Chemistry, vol. 268, No. 15, 1993, pp. 10863-10869.
The Epithelin Precursor Encodes Two Proteins with Opposing Activities on Epithelial Cell Growth, Plowman, G. et al., The Journal of Biological Chemistry, vol. 267, No. 18, 1992, pp. 13073-13078.
Granulins, a Novel Class of Peptide from Leukocytes, Bateman, A. et al., Biochemical and Biophysical Research Communications, vol. 173, No. 3, 1990, pp. 1161-1168.
A Synthetic Fragment of Rat Transforming Growth Factor with Receptor Binding and Antigenic Properties, Nestor, J. et al., Biochemical and Biophysical Research Communications, vol. 129, No. 1, 1985, pp. 226-232.
In Vitro Deletional Mutagenesis for Bacterial Production of the 20,000-Dalton Form of Human Pituitary Growth Hormone, Adelman, J. et al., DNA, vol. 2, No. 3, 1983, pp. 183-193.
An In Vitro Model to Study Adipose Differentiation in Serum-Free Medium, Serrero, G. et al., Analytical Biochemistry 120, 1982, pp. 351-359.
Study of a Teratoma-Derived Adipogenic Cell Line 1246 and Isolation of an Insulin-Independent Variant in Serum-Free Medium, Serrero-Dave, G., Cancer Center, University of California, pp. 366-376.
Tumorigenicity Associated with Loss of Differentiation and of Response to Insulin in the Adipogenic Cell Line 1246, Serrero, G., In Vitro Cellular & Developmental Biology, vol. 21, No. 9, 1985, pp. 537-540.
Decreased Transforming Growth Factor-β Response and Binding in Insulin-independent Teratoma-Derived Cell Lines with Increased Tumorigenic Properties, Serrero, G. et al., Journal of Cellular Physiology, 149, 1991, pp. 503-511.
Growth Inhibition of Human Breast Cancer Cells in Vitro with an Antibody against the Type I Somatomedin Receptor, Arteaga, C. et al., Cancer Research 49, 1989, pp. 6237-6241.
The Biological Effects of a High Molecular Weight Form of IGF II in a Pluripotential Human Teratocarcinoma Cell Line, Schofield, P. et al., Anticancer Research 14, 1994, pp. 533-538.
Gene therapy of murine teratocarcinoma: Separate functions for insulin-like growth factors I and II in immunogenicity and differentiation, Trojan, J. et al., Proc. Natl. Acad. Sci. USA, vol. 91, 1994, pp. 6088-6092.
Treatment and Prevention of Rat Glioblastoma by Immunogenic C6 Cells Expressing Antisense Insulin-Like Growth Factor I RNA, Trojan, J. et al., Science, vol. 259, 1993, pp. 94-96.
Continuous cultures of fused cells secreting antibody of predefined specificity, Kohler, G. et al., Nature, vol. 256, 1975, pp. 495-497.
Production of Monoclonal Antibodies: Strategy and Tactics, de St. Groth, S.F. et al., Journal of Immunology Methods, 35, 1980, pp. 1-21.
Hybridoma Techniques, Schreier, M. et al., Cold Spring Harbor Laboratory, 1980.
Generation of antibody activity from immunoglobulin polypeptide chains produced in Escherichia coli, Cabilly, S. et al., Proc. Natl. Acad. Sci. USA, vol. 81, 1984, pp. 3273-3277.
Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains, Morrison, S. et al., Proc. Natl. Acad. Sci. USA, vol. 81, 1984, pp. 6851-6855.
Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells, Liu, A. et al., Proc. Natl. Acad. Sci. USA, vol. 84, 1987, pp. 3439-3443.
Escherichia coli Secretion of an Active Chimeric Antibody Fragment, Better, M. et al., Science, vol. 240, 1988, pp. 1041-1043.
Reshaping human antibodies for therapy, Riechmann, L. et al., Nature, vol. 332, 1988, pp. 323-327.
Antibody Humanization Using Monovalent Phage Display, Baca, M. et al., J. Biol. Chem., vol. 272, No. 16, 1997, pp. 10678-10684.
A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab, Rosok, M.J. et al., J. Biol. Chem., vol. 271, No. 37, 1996, pp. 22611-22618.
Improved Radioimaging and Tumor Localization with Monoclonal F(ab′), Wahl, R.L. et al., The Journal of Nuclear Medicine, vol. 24, No. 4, 1983, pp. 316-325.
Clinical Use of a Monoclonal Antibody to Bombesin-lik Peptide in Patients with Lung Cancer, Mulshine, J.L., Annals New York Academy of Sciences, pp. 360-372.
Antisense RNA inhibits splicing of pre-mRNA in vitro, Munroe, S.H., The EMBO Journal, vol. 7, No. 8, 1988, pp. 2523-2532.
Specific Synthesis of DNA in vitro via a Polymerase-Catalyzed Chain Reaction, Mulis, K.B. et al., Methods in Enzymology, vol. 155, 1987, pp. 335-350.
Antisense approaches to cancer gene therapy, Mercola, D. et al., Cancer Gene Therapy, vol. 2, No. 1, 1995, pp. 47-59.
Gene inhibition using antisense oligodeoxynucleotides, Wagner, R. W., Nature, vol. 372, 1994, pp. 333-335.
Molecular Cloning: A Laboratory Manual, Maniatis, T. et al., Cold Spring Harbor Laboratory, 1982.
Design and Application of Antisense Oligonucleotides in Cell Culture, in Vivo, and as Therapeutic Agents, Brysch, W. et al., Cellular and Molecular Neurobiology, vol. 14, No. 5, 1994, pp. 557-568.
Rational Design of Sequence-specific Oncogene Inhibitors Based on Antisense and Antigene Oligonucleotides, Helene, C., Eur. J. Cancer, vol. 27, No. 11, 1991, pp. 1466-1471.
Optimization of Antisense Oligodeoxynucleotide Structure for Targeting ber-abl mRNA, Giles, R.V. et al., Blood, vol. 86, No. 2, 1995, pp. 744-754.
Extending the chemistry that supports genetic information transfer in vivo: Phosphorothioate DNA, phosphorothioate RNA, 2′-O-methyl RNA, and methylphosphonate DNA, Thaler, D.S. et al., Proc. Natl. Acad. Sci. USA, vol. 93, 1996, pp. 1352-1356.
Oligonucleotides N3′-P5′ phosphoramidates as antisense agents, Gryaznov, S. et al., Nucleic Acids Research, vol. 24, No. 8, 1996, pp. 1508-1514.
Cationic liposomes improve stability and intracellular delivery of antisense oligonucleotides into CaSki cells, Lappalainen, K. et al., Biochimica et Biophysica Acta 1196, 1994, pp. 201-208.
Block of AIDS-Kaposi's Sarcomo(KS)Cell Growth, Angiogenesis, and Lesion Forma
A&G Pharmaceutical, Inc.
Dickstein , Shapiro, Morin & Oshinsky, LLP
Yu Misook
LandOfFree
Methods and kits for diagnosing tumorigenicity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and kits for diagnosing tumorigenicity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and kits for diagnosing tumorigenicity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3637919